SPDA1
MCID: SPN225
MIFTS: 73

Spondyloarthropathy 1 (SPDA1)

Categories: Bone diseases, Genetic diseases, Muscle diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Spondyloarthropathy 1

MalaCards integrated aliases for Spondyloarthropathy 1:

Name: Spondyloarthropathy 1 56 73 37
Ankylosing Spondylitis 56 12 74 52 25 73 36 29 6 42 15 17 71 32
Spondyloarthropathy, Susceptibility to, 1 56 13 39
Marie-Strumpell Spondylitis 56 52 73
Bechterew Syndrome 56 52 73
Spondylarthritis Ankylopoietica 25 73
Spondylitis, Ankylosing 25 43
Reiter Syndrome 73 71
Spda1 56 73
Ankylosing Spondylitis, Susceptibility to 56
Spondyloarthritis Ankylopoietica 25
Ankylosing Spondyloarthritis 52
Ankylosing Spondylarthritis 73
Spondylitis Ankylopoietica 25
Marie-Struempell Disease 25
Marie-Strumpell Disease 12
Rheumatoid Spondylitis 73
Spondylitis Ankylosans 73
Spondylitis Ankylosing 54
Spondylarthropathies 71
Arthritis, Psoriatic 71
Psoriatic Arthritis 73
Bekhterev's Disease 12
Arthritis, Reactive 71
Reactive Arthritis 73
Bekhterev Syndrome 12
Bechterew Disease 25
As 25

Characteristics:

OMIM:

56
Inheritance:
multifactorial

Miscellaneous:
overall prevalence is between 0.5 and 14 per 100,000 people per year
genetic heterogeneity (see spondyloarthropathy, susceptibility to, 2 )
spondyloarthropathy includes a spectrum of related disorders, including, 1 - ankylosing spondylitis (as), 2 - a subset of psoriatic arthritis (psa), 3 - reactive arthritis (rea), 4 - arthritis associated with inflammatory bowel disease (aibd), 5 - undifferentiated spondyloarthropathy (uspa)


HPO:

31
spondyloarthropathy 1:
Inheritance multifactorial inheritance heterogeneous


Classifications:



External Ids:

Disease Ontology 12 DOID:7147
OMIM 56 106300
OMIM Phenotypic Series 56 PS106300
KEGG 36 H01674
ICD9CM 34 720.0
NCIt 49 C84564
SNOMED-CT 67 9631008
ICD10 32 M45
UMLS 71 C0003872 C0035012 C0038013 more

Summaries for Spondyloarthropathy 1

Genetics Home Reference : 25 Ankylosing spondylitis is a form of ongoing joint inflammation (chronic inflammatory arthritis) that primarily affects the spine. This condition is characterized by back pain and stiffness that typically appear in adolescence or early adulthood. Over time, back movement gradually becomes limited as the bones of the spine (vertebrae) fuse together. This progressive bony fusion is called ankylosis. The earliest symptoms of ankylosing spondylitis result from inflammation of the joints between the pelvic bones (the ilia) and the base of the spine (the sacrum). These joints are called sacroiliac joints, and inflammation of these joints is known as sacroiliitis. The inflammation gradually spreads to the joints between the vertebrae, causing a condition called spondylitis. Ankylosing spondylitis can involve other joints as well, including the shoulders, hips, and, less often, the knees. As the disease progresses, it can affect the joints between the spine and ribs, restricting movement of the chest and making it difficult to breathe deeply. People with advanced disease are also more prone to fractures of the vertebrae. Ankylosing spondylitis affects the eyes in up to 40 percent of cases, leading to episodes of eye inflammation called acute iritis. Acute iritis causes eye pain and increased sensitivity to light (photophobia). Rarely, ankylosing spondylitis can also cause serious complications involving the heart, lungs, and nervous system.

MalaCards based summary : Spondyloarthropathy 1, also known as ankylosing spondylitis, is related to interstitial nephritis and klebsiella pneumonia, and has symptoms including pain, stiffness in the spine and stiffness in the neck. An important gene associated with Spondyloarthropathy 1 is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Antigen processing and presentation and Innate Immune System. The drugs Tazarotene and Meloxicam have been mentioned in the context of this disorder. Affiliated tissues include Placenta and Umbilical Cord, and related phenotypes are kyphosis and arrhythmia

Disease Ontology : 12 A bone inflammation disease that results in inflammation in the joints of the spine and pelvis. The disease has symptom pain, has symptom stiffness in the spine, has symptom stiffness in the neck, has symptom stiffness in the hips, has symptom stiffness in the jaw and has symptom stiffness in the rib cage.

NIH Rare Diseases : 52 Ankylosing spondylitis (AS) is a type of chronic, inflammatory arthritis that mainly affects the spine. It usually begins with inflammation of the joints between the pelvic bones and spine, gradually spreading to the joints between the vertebrae. Signs and symptoms usually begin in adolescence or early adulthood and may include back pain and stiffness. Back movement gradually becomes more limited as the vertebrae fuse together. The condition may also affect the shoulders; ribs; hips; knees; and feet; as well as the eyes; bowel; and very rarely, the heart and lungs. AS is likely caused by a combination of genetic and environmental factors ; variations in several genes are thought to affect the risk to develop AS. In most cases, treatment involves exercise and medications to relieve pain and inflammation.

OMIM : 56 Spondyloarthropathy (SpA), one of the commonest chronic rheumatic diseases, includes a spectrum of related disorders comprising the prototype ankylosing spondylitis (AS), a subset of psoriatic arthritis (PsA), reactive arthritis (ReA), arthritis associated with inflammatory bowel disease, and undifferentiated spondyloarthropathy (Miceli-Richard et al., 2004). These phenotypes are difficult to differentiate because they may occur simultaneously or sequentially in the same patient. Studies have suggested that a predominant shared component, including HLA-B27, predisposes to all phenotypic subsets, and that these subsets should be considered as various phenotypic expressions of the same disease (Said-Nahal et al., 2000, Said-Nahal et al., 2001). Braun and Sieper (2007) provided a detailed review of ankylosing spondylitis, including clinical features, pathogenesis, and management. (106300)

MedlinePlus : 42 Ankylosing spondylitis is a type of arthritis of the spine. It causes inflammation between your vertebrae, which are the bones that make up your spine, and in the joints between your spine and pelvis. In some people, it can affect other joints. AS is more common and more severe in men. It often runs in families. The cause is unknown, but it is likely that both genes and factors in the environment play a role. Early symptoms of AS include back pain and stiffness. These problems often start in late adolescence or early adulthood. Over time, AS can fuse your vertebrae together, limiting movement. Some people have symptoms that come and go. Others have severe, ongoing pain. A diagnosis of AS is based on your medical history and a physical examination. You may also have imaging or blood tests. AS has no cure, but medicines can relieve symptoms and may keep the disease from getting worse. Eating a healthy diet, not smoking, and exercising can also help. In rare cases, you may need surgery to straighten the spine. NIH: National Institute of Arthritis and Musculoskeletal and Skin Disease

KEGG : 36 Ankylosing spondylitis (AS), formerly also known as Bechterew's disease, is a rheumatic disease of the axial skeleton that mainly affects the spine and the sacroiliac joint in the pelvis. AS is one of a group of inflammatory diseases, called spondyloarthritides, which share features. This disease is characterized by erosion, sclerosis, and ossification, which may result in complete fusion and rigidity of the spine. Regarding extra-articular manifestations, the most frequent is anterior uveitis. The major functional losses occur during the first 10 years of disease. It usually begins in the second or third decade of life, preferentially in HLA-B27-positive Caucasian males. Its etiology and pathogenesis are not completely understood, but the most prevalent hypothesis involves immune mediation as its major mechanism, including several cytokines. To date, more than 40 genetic variants have been identified that influence the risk of developing AS, including HLA alleles such as HLA-B27. Non-steroid anti-inflammatory drugs (NSAIDs) are used to reduce pain and inflammation. Additional disease-modifying anti-rheumatic drugs (DMARDs) are prescribed to slowdown disease progression. The most frequently applied biological agents approved for AS are TNF alpha inhibitors. The IL-17 inhibitor secukinumab has been recently approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, and AS.

UniProtKB/Swiss-Prot : 73 Spondyloarthropathy 1: A chronic rheumatic disease with multifactorial inheritance. It includes a spectrum of related disorders comprising ankylosing spondylitis, a subset of psoriatic arthritis, reactive arthritis (e.g. Reiter syndrome), arthritis associated with inflammatory bowel disease and undifferentiated spondyloarthropathy. These disorders may occur simultaneously or sequentially in the same patient, probably representing various phenotypic expressions of the same disease. Ankylosing spondylitis is the form of rheumatoid arthritis affecting the spine and is considered the prototype of seronegative spondyloarthropathies. It produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints.

Wikipedia : 74 Ankylosing spondylitis (AS) is a type of arthritis in which there is a long-term inflammation of the... more...

Related Diseases for Spondyloarthropathy 1

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 1 Spondyloarthropathy 2
Spondyloarthropathy 3 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 10663)
# Related Disease Score Top Affiliating Genes
1 interstitial nephritis 32.6 CRP CD40LG CCR6 B2M
2 klebsiella pneumonia 32.5 IL17A CRP CD40LG CCR6
3 dermatitis 32.4 TNF NOD2 IL17A CCR6
4 lyme disease 32.4 TNF IL17A CRP CD40LG
5 pulmonary disease, chronic obstructive 32.4 TNF TLR4 IL17A CRP CCR6
6 mycoplasma pneumoniae pneumonia 32.4 TNF IL17A CRP CD40LG
7 vascular disease 32.3 TNF TLR4 MMP3 CRP CD40LG
8 antiphospholipid syndrome 32.3 TNF TLR4 CRP CD40LG
9 acute disseminated encephalomyelitis 32.3 HLA-B CD40LG CCR6
10 respiratory failure 32.3 TNF TLR4 CRP CD40LG CCR6
11 listeriosis 32.3 TNF TLR4 CCR6
12 progressive multifocal leukoencephalopathy 32.3 TNF CD40LG CCR6
13 herpes zoster 32.3 TNFRSF1B TNF HLA-B CRP CD40LG CCR6
14 hidradenitis suppurativa 32.3 TNF TLR4 NOD2 IL17A
15 osteoarthritis 32.3 TNFSF11 TNF MMP3 IL17A CRP
16 bursitis 32.2 TNFRSF1B TNF CRP
17 cytomegalovirus infection 32.2 TNF HLA-B B2M
18 langerhans cell histiocytosis 32.2 TNFSF11 IL17A CD163 CCR6
19 systemic scleroderma 32.2 TNF IL17A CRP CD40LG CCR6
20 proteasome-associated autoinflammatory syndrome 1 32.2 TNF TLR4 IL17A CRP
21 cartilage disease 32.2 TNFRSF1B TNF CRP
22 bacterial meningitis 32.2 TNF TLR4 IL17A CRP
23 blau syndrome 32.2 TNF TLR4 NOD2
24 vasculitis 32.2 TNFRSF1B TNF IL17A HLA-B CRP CD40LG
25 dermatitis, atopic 32.2 TNF TLR4 NOD2 IL17A CCR6
26 kawasaki disease 32.2 TNF MMP3 IL17A CRP CD40LG
27 neuromyelitis optica 32.2 IL17A CRP CD40LG
28 streptococcus pneumonia 32.2 TNF TLR4 IL17A CRP CD40LG CCR6
29 rubella 32.2 TNFRSF1B TNF TLR4 HLA-B CD40LG
30 neutropenia 32.2 TNFRSF1A TNF TLR4 CRP CD40LG
31 adult-onset still's disease 32.2 TNFRSF1A TNF CRP
32 acute cystitis 32.2 TNF TLR4 CRP CD40LG CCR6
33 endocarditis 32.2 TNFRSF1B TNF IL17A CRP
34 thrombocytopenia due to platelet alloimmunization 32.2 IL17A CD40LG CCR6
35 short syndrome 32.2 TNFRSF1B TNF CRP
36 juvenile rheumatoid arthritis 32.2 TNFRSF1B TNFRSF1A TNF MMP3 CRP
37 leishmaniasis 32.2 TNFRSF1A TNF TLR4 IL17A CRP
38 bronchiolitis obliterans 32.2 TNF TLR4 IL17A CRP
39 guillain-barre syndrome 32.2 TNFRSF1B TNFRSF1A TNF CD40LG CCR6
40 toxoplasmosis 32.1 TNFRSF1A TNF TLR4 CD40LG
41 aspergillosis 32.1 TNFRSF1B TNF TLR4 NOD2 CCR6
42 mevalonic aciduria 32.1 TNFRSF1B TNFRSF1A TNF NOD2
43 churg-strauss syndrome 32.1 TNF IL17A CD40LG
44 cystitis 32.1 TNF TLR4 IL17A CRP
45 chickenpox 32.1 TNFRSF1B TNF CRP CD40LG CCR6
46 retinal vasculitis 32.1 TNFRSF1B TNF CD40LG CCR6
47 vaginal discharge 32.1 TNF CRP CD40LG
48 legionnaire disease 32.1 TLR4 CRP CD40LG
49 conjunctivitis 32.1 TNFRSF1A TNF HLA-B
50 sarcoidosis 1 32.1 TNFRSF1B TNF NOD2 CRP CD40LG CCR6

Comorbidity relations with Spondyloarthropathy 1 via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypertension, Essential Osteoporosis
Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Spondyloarthropathy 1:



Diseases related to Spondyloarthropathy 1

Symptoms & Phenotypes for Spondyloarthropathy 1

Human phenotypes related to Spondyloarthropathy 1:

31 (show all 10)
# Description HPO Frequency HPO Source Accession
1 kyphosis 31 HP:0002808
2 arrhythmia 31 HP:0011675
3 psoriasiform dermatitis 31 HP:0003765
4 inflammation of the large intestine 31 HP:0002037
5 back pain 31 HP:0003418
6 aortic regurgitation 31 HP:0001659
7 enthesitis 31 HP:0100686
8 hip osteoarthritis 31 HP:0008843
9 anterior uveitis 31 HP:0012122
10 sacroiliac arthritis 31 HP:0012317

Symptoms via clinical synopsis from OMIM:

56
Head And Neck Eyes:
anterior uveitis

Abdomen Gastrointestinal:
inflammatory bowel disease (crohn disease and ulcerative colitis)

Skeletal Pelvis:
arthritis (hip)

Skin Nails Hair Skin:
psoriasis

Cardiovascular Heart:
aortic insufficiency
aortitis
cardiac conduction abnormalities

Skeletal Spine:
accentuated kyphosis
back stiffness
nocturnal back pain
ankylosing spondylitis
sacroiliitis
more
Skeletal Limbs:
peripheral arthritis (oligoarticular or polyarticular)
peripheral enthesitis

Laboratory Abnormalities:
hla-b27 haplotype association (95% patients)
rheumatoid factor negative

Clinical features from OMIM:

106300

Symptoms:

12
  • pain
  • stiffness in the spine
  • stiffness in the neck
  • stiffness in the hips
  • stiffness in the jaw
  • stiffness in the rib cage

UMLS symptoms related to Spondyloarthropathy 1:


back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Spondyloarthropathy 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 ANKH B2M CCR6 CD163 CD40LG IL17A
2 homeostasis/metabolism MP:0005376 10.1 ANKH B2M CCR6 CD163 CD40LG CRP
3 cardiovascular system MP:0005385 10.07 ANKH B2M CCR6 CD163 CD40LG CRP
4 immune system MP:0005387 10.03 ANKH B2M CCR6 CD163 CD40LG CRP
5 respiratory system MP:0005388 9.56 ANKH CD163 IL17A TLR4 TNF TNFRSF1A
6 skeleton MP:0005390 9.32 ANKH CD40LG IL17A MMP3 NOD2 TLR4

Drugs & Therapeutics for Spondyloarthropathy 1

Drugs for Spondyloarthropathy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
2
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
3
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Loxoprofen Approved Phase 4 68767-14-6, 80382-23-6 3965
6
Aceclofenac Approved, Investigational Phase 4 89796-99-6
7
Pamidronate Approved Phase 4 40391-99-9 4674
8
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
11
tannic acid Approved Phase 4 1401-55-4
12
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
13
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
14
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
15
Atorvastatin Approved Phase 4 134523-00-5 60823
16
carbamide peroxide Approved Phase 4 124-43-6
17
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
18
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
19
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
20
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
21
Hydroxychloroquine Approved Phase 4 118-42-3 3652
22
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
23
Etanercept Approved, Investigational Phase 4 185243-69-0
24
Acetaminophen Approved Phase 4 103-90-2 1983
25
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
26
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
27 Natriuretic Peptide, Brain Phase 4
28 Tocolytic Agents Phase 4
29 Vaccines Phase 4
30 Mitogens Phase 4
31 Endothelial Growth Factors Phase 4
32 Tripterygium Phase 4
33 Cholestyramine Resin Phase 4
34 Anesthetics Phase 4
35 Anti-Arrhythmia Agents Phase 4
36 Triamcinolone diacetate Phase 4
37 triamcinolone acetonide Phase 4
38 Triamcinolone hexacetonide Phase 4
39 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
40 Insulin, Globin Zinc Phase 4
41 Sodium Channel Blockers Phase 4
42 Chlorhexidine gluconate Phase 4
43 Vasoconstrictor Agents Phase 4
44 insulin Phase 4
45 Diuretics, Potassium Sparing Phase 4
46 Anesthetics, Local Phase 4
47 Angiogenesis Inhibitors Phase 4
48 Hypolipidemic Agents Phase 4
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
50 Anticholesteremic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 803)
# Name Status NCT ID Phase Drugs
1 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
2 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Unknown status NCT02492217 Phase 4 Adalimumab
3 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
4 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
5 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
6 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
7 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
8 Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA) Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
9 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
10 Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis Unknown status NCT00573651 Phase 4
11 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
12 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
13 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
14 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
15 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
16 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
17 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
18 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
19 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
20 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
21 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Completed NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
22 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
23 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
24 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
25 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
26 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
27 Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation Completed NCT03880968 Phase 4 tapering or discontinuation of etanercept
28 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
29 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
30 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
31 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
32 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
33 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
34 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
35 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
36 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
37 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
38 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
39 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
40 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 AIN457/Secukinumab Placebo; Biological: AIN457/Secukinumab
41 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
42 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Completed NCT02509026 Phase 4
43 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
44 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
45 Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel® Completed NCT00127842 Phase 4 Etanercept
46 A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive Completed NCT03151551 Phase 4 Ixekizumab;Adalimumab
47 A Randomized, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects With Psoriatic Arthritis. Completed NCT00245960 Phase 4 etanercept
48 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
49 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
50 A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL) Completed NCT02814175 Phase 4 methotrexate (MTX)

Search NIH Clinical Center for Spondyloarthropathy 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Auranofin
Aurothioglucose
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Etanercept
Ibuprofen
Naproxen
Naproxen sodium
Piroxicam
solufenum

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spondyloarthropathy 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells to treat ankylosing spondylitis
Embryonic/Adult Cultured Cells Related to Spondyloarthropathy 1:
Umbilical cord-derived mesenchymal stem cells (family)
Placenta-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: spondylitis, ankylosing

Genetic Tests for Spondyloarthropathy 1

Genetic tests related to Spondyloarthropathy 1:

# Genetic test Affiliating Genes
1 Ankylosing Spondylitis 29 HLA-B

Anatomical Context for Spondyloarthropathy 1

MalaCards organs/tissues related to Spondyloarthropathy 1:

40
Bone, T Cells, Eye, Testes, Lung, Heart, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spondyloarthropathy 1:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
3 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Spondyloarthropathy 1

Articles related to Spondyloarthropathy 1:

(show top 50) (show all 13676)
# Title Authors PMID Year
1
Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. 61 56 6
8053961 1994
2
Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. 56 61 54
10861282 2000
3
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. 56 61
21743469 2011
4
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. 61 56
20062062 2010
5
Association of chromosome 2q36.1-36.3 and autosomal dominant transmission in ankylosing spondylitis: results of genetic studies across generations of Han Chinese families. 61 56
19416804 2009
6
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. 56 61
17952073 2007
7
Ankylosing spondylitis. 56 61
17448825 2007
8
Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. 56 61
15051216 2004
9
Identification of major loci controlling clinical manifestations of ankylosing spondylitis. 56 61
12905477 2003
10
Chronic synovitis and HLA B27 in patients with severe haemophilia. 6 61
12648975 2003
11
Ankylosing spondylitis, HLA B27, and beyond. 61 56
9519942 1998
12
Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. 56 61
9336417 1997
13
The sex ratios of probands and of secondary cases in conditions of multifactorial inheritance where liability varies with sex. 61 56
1999831 1991
14
Relative role of genetic and environmental factors in disease expression: sib pair analysis in ankylosing spondylitis. 61 56
2912465 1989
15
Complete sequence of HLA-B27 cDNA identified through the characterization of structural markers unique to the HLA-A, -B, and -C allelic series. 56 61
3485286 1986
16
Ankylosing spondylitis is part of a multifactorial syndrome: hereditary multifocal relapsing inflammation (HEMRI). 61 56
6332689 1984
17
Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls. 61 56
6606431 1983
18
Family studies in Bechterew's syndrome (ankylosing spondylitis) III. Genetics. 56 61
6604602 1983
19
HLA B27 and the genetics of ankylosing spondylitis. 61 56
107868 1978
20
Histocompatibility typing and the counseling of families with ankylosing spondylitis. 61 56
657578 1978
21
HLA B27 in ankylosing spondylitis in India. 61 56
68310 1977
22
Striking prevalence of ankylosing spondylitis in "healthy" w27 positive males and females. 56 61
126380 1975
23
HL-A27 and ankylosing spondylitis in B.C. Indians. 61 56
1185744 1975
24
Ankylosing spondylitis and HL-A. A genetic disease plus? 61 56
1130424 1975
25
Ankylosing spondylitis and HL-A 27. 56 61
4123836 1973
26
High association of an HL-A antigen, W27, with ankylosing spondylitis. 61 56
4688372 1973
27
Human lymphocyte antigen association in ankylosing spondylitis. 61 56
4694299 1973
28
Genetics of ankylosing spondylitis. 56 61
6082899 1967
29
A family study of rheumatoid (ankylosing) spondylitis. 56 61
14454080 1962
30
Hereditary factors in rheumatoid arthritis and ankylosing spondylitis. 56 61
13869952 1961
31
Ankylosing spondylitis in two families showing involvement of female members only. With a search for linkage to genes determining blood group antigens. 56 61
14411096 1960
32
Heredity in ankylosing spondylitis. 56 61
13650428 1959
33
The inheritance of spondylitis rhizomelique (ankylosing spondylitis) in the K. family. 61 56
14783304 1950
34
Olfactory and Gustatory Dysfunction in a COVID-19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report. 61 42
32476306 2020
35
Efficacy of needle-knife combined with etanercept treatment regarding disease activity and hip joint function in ankylosing spondylitis patients with hip joint involvement: A randomized controlled study. 42 61
32384461 2020
36
Sleep apnea-hypopnea syndrome caused by ankylosing spondylitis: A case report. 42 61
32384469 2020
37
HLA-B27 lacking associated beta2-microglobulin rearranges to auto-display or cross-display residues 169-181: a novel molecular mechanism for spondyloarthropathies. 56
15388324 2004
38
Significant linkage to spondyloarthropathy on 9q31-34. 56
15234954 2004
39
Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. 56
11762681 2001
40
The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Français d'Etude Génétique des Spondylarthropathies. 56
10857795 2000
41
HLA-B27 and spondyloarthropathy: value for early diagnosis? 56
7562959 1995
42
HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. 56
7791441 1995
43
Familial aggregation of undifferentiated spondyloarthropathy associated with HLA-B7. 56
7702399 1995
44
A hypothesis for the HLA-B27 immune dysregulation in spondyloarthropathy: contributions from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution. 56
8415702 1993
45
Autosomal dominant spondyloarthropathy: no linkage to the type II collagen gene. 56
2300126 1990
46
Autosomal dominant spondyloarthropathy. 56
2927470 1989
47
Progressive ankylosis in mice. An animal model of spondylarthropathy. I. Clinical and radiographic findings. 56
3190783 1988
48
Progressive ankylosis, a new skeletal mutation in the mouse. 56
7276519 1981
49
Joseph J. Bunim Memorial Lecture. HLA-B27 and the inheritance of susceptibility to rheumatic disease. 56
782462 1976
50
The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis. 61 54
20111975 2010

Variations for Spondyloarthropathy 1

ClinVar genetic disease variations for Spondyloarthropathy 1:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HLA-B HLA-B, HLA-B27undetermined variant risk factor 14908

Expression for Spondyloarthropathy 1

Search GEO for disease gene expression data for Spondyloarthropathy 1.

Pathways for Spondyloarthropathy 1

Pathways related to Spondyloarthropathy 1 according to KEGG:

36
# Name Kegg Source Accession
1 Antigen processing and presentation hsa04612

Pathways related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 TNFSF11 TNFRSF1B TNFRSF1A TNF TLR4 TAPBP
2
Show member pathways
13.37 TNFSF11 TNFRSF1B TNFRSF1A TNF TLR4 IL17A
3
Show member pathways
13.23 ZNF354A TNFSF11 TNFRSF1B TNFRSF1A TNF IL17A
4
Show member pathways
13.13 TNFSF11 TNFRSF1B TNFRSF1A TNF NOD2 MMP3
5
Show member pathways
12.86 TNFRSF1B TNFRSF1A TNF TLR4 TAPBP HLA-B
6
Show member pathways
12.81 TNF TAPBP IL17A HLA-B CD40LG B2M
7
Show member pathways
12.76 TNFRSF1A TNF TLR4 TAPBP HLA-B B2M
8 12.74 ZNF354A TNFRSF1A TNF TAPBP HLA-B B2M
9
Show member pathways
12.66 TNFRSF1B TNFRSF1A TNF TLR4 CD40LG
10
Show member pathways
12.49 TNFSF11 TNFRSF1B TNFRSF1A TNF TLR4 CD40LG
11 12.3 TNFRSF1A TNF HLA-B B2M
12
Show member pathways
12.29 TNFRSF1B TNFRSF1A TNF CCR6
13
Show member pathways
12.22 TNFRSF1A TNF TLR4 CD40LG
14 12.19 TNFRSF1A TNF TLR4 NOD2
15 12.18 TNFSF11 TNFRSF1B TNFRSF1A TNF CD40LG
16 12.01 TNFSF11 TNFRSF1B TNFRSF1A TNF IL17A CD40LG
17 11.94 TNFRSF1B TNF MMP3 IL17A
18 11.85 TNFRSF1B TNFRSF1A TNF NOD2 MMP3
19 11.78 TNFSF11 TNFRSF1A TNF TLR4 CD40LG
20 11.74 TNF IL17A CCR6
21 11.67 TNFRSF1B TNFRSF1A TNF
22 11.62 TNFSF11 TNF TLR4 MMP3 IL17A
23
Show member pathways
11.6 TNFRSF1A TNF MMP3 CD40LG
24
Show member pathways
11.52 TNFRSF1B TNFRSF1A TNF
25 11.5 TNF TLR4 CD40LG
26 11.49 TNFRSF1B TNFRSF1A TNF
27 11.49 TNFRSF1B TNFRSF1A TNF TLR4
28
Show member pathways
11.47 TNFSF11 TNFRSF1B TNFRSF1A TNF CD40LG
29
Show member pathways
11.34 TNFRSF1B TNFRSF1A TNF
30 11.3 TNFRSF1B TNFRSF1A CD40LG
31 11.28 TNFRSF1B TNFRSF1A TNF
32 11.12 TAPBP HLA-B B2M
33 11.07 TNFRSF1A TNF NOD2
34
Show member pathways
10.88 TNFSF11 TNFRSF1B TNFRSF1A TNF CD40LG

GO Terms for Spondyloarthropathy 1

Cellular components related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 TNFSF11 TNFRSF1B TNFRSF1A TNF MMP3 IL17A
2 integral component of plasma membrane GO:0005887 9.81 TNFSF11 TNFRSF1A TNF TLR4 HLA-B CD40LG
3 phagocytic vesicle membrane GO:0030670 9.58 TAPBP HLA-B B2M
4 cell surface GO:0009986 9.56 TNFRSF1A TNF TLR4 NOD2 HLA-B CD40LG
5 MHC class I protein complex GO:0042612 9.43 HLA-B B2M
6 MHC class I peptide loading complex GO:0042824 9.37 TAPBP B2M
7 tumor necrosis factor receptor superfamily complex GO:0002947 9.26 TNFRSF1B TNFRSF1A
8 external side of plasma membrane GO:0009897 9.17 TNF TLR4 IL17A CD40LG CD163 CCR6

Biological processes related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.91 TNFRSF1B TNF TLR4 NOD2
2 defense response GO:0006952 9.88 TNFRSF1A TNF NOD2 HLA-B
3 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.84 TAPBP HLA-B B2M
4 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.82 TNFRSF1A TNF TLR4
5 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 TNF TLR4 NOD2
6 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.8 TNFSF11 TNFRSF1A TNF TLR4 NOD2
7 cytokine-mediated signaling pathway GO:0019221 9.8 TNFSF11 TNFRSF1B TNFRSF1A TNF MMP3 IL17A
8 positive regulation of MAP kinase activity GO:0043406 9.79 TNFSF11 TNF NOD2
9 positive regulation of interleukin-6 production GO:0032755 9.79 TNF TLR4 NOD2
10 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.77 TNFRSF1B TNFRSF1A TNF
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.77 TNFSF11 TNF TLR4 NOD2 CD40LG
12 positive regulation of interleukin-6 secretion GO:2000778 9.74 TNF TLR4 IL17A
13 positive regulation of JNK cascade GO:0046330 9.73 TNFSF11 TNF TLR4 NOD2
14 positive regulation of interleukin-1 beta secretion GO:0050718 9.71 USP50 TLR4 NOD2
15 positive regulation of interleukin-8 production GO:0032757 9.69 TNF TLR4 NOD2
16 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.68 TNF TLR4
17 positive regulation of ceramide biosynthetic process GO:2000304 9.68 TNFRSF1A TNF
18 detection of bacterium GO:0016045 9.68 NOD2 HLA-B
19 regulation of neuroinflammatory response GO:0150077 9.67 TNFRSF1B MMP3
20 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.67 TAPBP B2M
21 negative regulation of lipid storage GO:0010888 9.67 TNF CRP
22 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.67 TAPBP HLA-B B2M
23 positive regulation of NLRP3 inflammasome complex assembly GO:1900227 9.66 USP50 TLR4
24 cellular response to nicotine GO:0071316 9.65 TNF B2M
25 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.65 TNF IL17A
26 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.65 HLA-B B2M
27 positive regulation of interleukin-10 production GO:0032733 9.65 TLR4 NOD2 CD40LG
28 tumor necrosis factor-mediated signaling pathway GO:0033209 9.65 TNFSF11 TNFRSF1B TNFRSF1A TNF CD40LG
29 regulation of establishment of endothelial barrier GO:1903140 9.64 TNFRSF1A TNF
30 death-inducing signaling complex assembly GO:0071550 9.63 TNFRSF1A TNF
31 positive regulation of interleukin-12 biosynthetic process GO:0045084 9.63 TLR4 IL17A
32 positive regulation of osteoclast differentiation GO:0045672 9.63 TNFSF11 TNF IL17A
33 regulation of immunoglobulin secretion GO:0051023 9.59 TNF CD40LG
34 aortic valve development GO:0003176 9.58 TNFRSF1B TNFRSF1A
35 negative regulation of extracellular matrix constituent secretion GO:0003332 9.56 TNFRSF1B TNFRSF1A
36 inflammatory response GO:0006954 9.56 TNFRSF1B TNFRSF1A TNF TLR4 IL17A CRP
37 pulmonary valve development GO:0003177 9.55 TNFRSF1B TNFRSF1A
38 positive regulation of apoptotic process involved in morphogenesis GO:1902339 9.52 TNFRSF1B TNFRSF1A
39 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.46 TNF TLR4 NOD2 IL17A
40 immune response GO:0006955 9.32 TNFSF11 TNFRSF1B TNF TLR4 TAPBP IL17A

Molecular functions related to Spondyloarthropathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 TNFSF11 TNF IL17A CD40LG
2 tumor necrosis factor-activated receptor activity GO:0005031 9.16 TNFRSF1B TNFRSF1A
3 tumor necrosis factor binding GO:0043120 8.96 TNFRSF1B TNFRSF1A
4 tumor necrosis factor receptor binding GO:0005164 8.8 TNFSF11 TNF CD40LG

Sources for Spondyloarthropathy 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....